1. Home
  2. TNGX vs MANH Comparison

TNGX vs MANH Comparison

Compare TNGX & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • MANH
  • Stock Information
  • Founded
  • TNGX 2014
  • MANH 1990
  • Country
  • TNGX United States
  • MANH United States
  • Employees
  • TNGX N/A
  • MANH N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • MANH Computer Software: Prepackaged Software
  • Sector
  • TNGX Health Care
  • MANH Technology
  • Exchange
  • TNGX Nasdaq
  • MANH Nasdaq
  • Market Cap
  • TNGX 990.5M
  • MANH N/A
  • IPO Year
  • TNGX N/A
  • MANH 1998
  • Fundamental
  • Price
  • TNGX $9.91
  • MANH $249.83
  • Analyst Decision
  • TNGX Strong Buy
  • MANH Strong Buy
  • Analyst Count
  • TNGX 8
  • MANH 7
  • Target Price
  • TNGX $14.86
  • MANH $257.43
  • AVG Volume (30 Days)
  • TNGX 877.3K
  • MANH 520.2K
  • Earning Date
  • TNGX 08-05-2024
  • MANH 07-23-2024
  • Dividend Yield
  • TNGX N/A
  • MANH N/A
  • EPS Growth
  • TNGX N/A
  • MANH 39.91
  • EPS
  • TNGX N/A
  • MANH 3.05
  • Revenue
  • TNGX $37,232,000.00
  • MANH $962,264,000.00
  • Revenue This Year
  • TNGX N/A
  • MANH $13.27
  • Revenue Next Year
  • TNGX $2.40
  • MANH $11.60
  • P/E Ratio
  • TNGX N/A
  • MANH $82.76
  • Revenue Growth
  • TNGX 49.72
  • MANH 18.92
  • 52 Week Low
  • TNGX $2.88
  • MANH $182.97
  • 52 Week High
  • TNGX $13.03
  • MANH $266.94
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 58.89
  • MANH 61.80
  • Support Level
  • TNGX $8.93
  • MANH $215.62
  • Resistance Level
  • TNGX $9.96
  • MANH $245.00
  • Average True Range (ATR)
  • TNGX 0.61
  • MANH 7.21
  • MACD
  • TNGX -0.01
  • MANH -1.07
  • Stochastic Oscillator
  • TNGX 88.78
  • MANH 88.17

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Share on Social Networks: